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Abstract
Resistance to activated protein C is one of the most common
inherited disorders associated with hereditary thrombophilia.
A missense mutation in the gene coding for coagulation factor
V (CF V Leiden) and which renders this procoagulant factor
resistant to inactivation by activated protein C results in an
inherited risk for venous thrombosis.   Recently, another
mutation has been identified in the prothrombin gene (CF II
G20210A) which was also associated with increased risk for
venous thrombosis. In this study, we sought to establish the
frequency of the two alleles in a random sample of Maltese
newborn and compare these with the frequencies of the same
alleles among senior citizens and patients with clinical
thrombophilia.
The control population of 554 newborn samples processed
for the same point mutations gave 13 (2.3%) who were CF V
Leiden heterozygotes and 7 (2.7%) who were CF II G20210A
heterozygotes. Neither homozygotes nor trans-heterozygotes
(i.e. CF V Leden and CF II20210A heterozygotes) were
observed.
The 348 senior citizens  gave 9 (2.6%) CF V Leiden
heterozygotes and 8 (2.4%) CF II G20210A heterozygotes.
Neither homozygotes nor trans-heterozygotes (i.e. CF V Leden
and CF II20210A heterozygotes) were observed. The 328
patients referred to the Laboratory of Molecular Genetics,
University of Malta, with clinical thrombosis gave  23 (7.01%)
CF V Leiden heterozygotes and 24 (7.31%) CF II G20210A
heterozygous.   One patient was found to be trans-heterozygous
for the two mutations.
The data suggested that although CF V G1691A and CF II
G20210A may increase risk for thrombophilia, they do not
impact on the survival of the carriers, but the
transheterozygozity may also confer increased risk.   The high
allele frequency may be best explained by positive natural
selection.
Introduction
The mutation in coagulation factor V (CF V) G1691A,
known as factor V Leiden1, and the recently described mutation
in the prothrombin (CF II) gene G20210A2 are the two most
prevalent known causes of inherited thrombophilia. The
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impaired neutralization of thrombin or a failure to control the
generation of thrombin increases the risk of clinical
thrombosis.3 Since inherited hypercoagulability is a persistent,
lifelong condition, whereas thrombosis occurs only
episodically, one might argue that all thrombotic events must
be precipitated by an acquired thrombogenic trigger.   In many
cases, the transient risk factor is clinically apparent (e.g., the
postoperative state, immobilization, or the peripartum period).
In others, in which thrombosis is considered to be idiopathic,
the acquired trigger is probably a sub clinical thrombogenic
stimulus.   Thus, many cases of venous thrombosis may involve
the convergence of one or more inherited prothrombotic
mutations (leading to a lifelong state of hypercoagulability) and
an acquired thrombogenic insult that precipitates the actual
clinical event.4  In patients with relatively low base-line degrees
of hypercoagulability (e.g., those without any, or with a single
mutation, such as CF V Leiden), a major, clinically clear
stimulus would be required to trigger the thrombotic episode.
In contrast, patients with higher base-line degrees of
hypercoagulability (e.g., those with multiple mutations in the
coagulation pathway) would require only relatively minor,
often subclinical, acquired insults to precipitate thrombosis.
In haemostasis, CF V is activated by thrombin when the
latter is produced by the action of CF Xa on prothrombin (CF
II); CF Va then acts as a cofactor of CF Xa and together they
associate with Ca2+ on the phospholipid surface of platelets or
endothelia to form an active “prothrombinase” that converts
additional prothrombin to thrombin.5  CF Va catalyses the rate
of CF Xa mediated prothrombin activation by a 1,000 fold.6
CF Va is inactivated by activated protein C thus limiting
thrombin formation from prothrombinase. However, the CF
V G1691A mutant resists inactivation leading to excess
thrombin generation and predisposition to thrombosis.6  CF
V Leiden is a common mutation in Caucasians, with a
heterozygote frequency ranging from 2% to 15% in several
populations.7,8 However, it also shows important regional
differences ranging from 2% in South Europe to 16% in parts
of North Europe.7  The risk of thrombosis is increased sevenfold
in heterozygotes and 80-fold in homozygotes as compared with
non carriers.9   In Southeast Asia and Africa the frequency of
the mutation is less than 1%.7
The CF II G20210A mutation has also been associated with
increased prothrombin levels in the plasma.2    The thrombosis
risk is increased by two when plasma CF II levels exceed 115%
of normal.2,10     The frequency of the prothrombin variant in
Caucasian populations is about 2%.11 Within Europe the
mutation frequency shows a marked increase from 1.7% in the
North to 3% in the South. 11
Both these mutations can be co-inherited (trans-
heterozygotes) leading to much increased risk of thrombosis
possibly manifesting in younger patients and having increased
severity.
In this study we report the comparative frequencies of the
CF V Leiden and CF II G20210A alleles in a number of random
newborn, a number of senior citizens and patients referred for
investigation of clinical thrombotic episodes.  The data showed
that although there was no significant difference in frequencies
between the newborn and the senior citizens, thus excluding
effects on survival, a much higher frequency was found among
the patients with thrombosis.
Materials and Methods
The study was approved by the Research Ethics Review
Board of the Faculty of Medicine of the University of Malta.
The blood samples were collected by venipuncture in EDTA
vacutainers (Becton Dickinson Vacutainer Systems, UK)
anonymised and stored at a temperature of -20∞C in a locked
freezer.   Blood was collected from random senior citizens (348)
referred through the Haematology Department from the
outpatients clinic at St. Luke’s Hospital, Gwardamangia, Malta.
Umbilical cord blood samples (554) were collected daily from
the maternity ward at St. Luke’s Hospital and patients (328)
were referred for investigation in connection with clinical
thrombosis.
Genetic Analysis
DNA extraction was performed using the Nucleon!” BACC1
Kit (Amersham Life Science). DNA analysis for the 1691 G to
A substitution in the CF V gene was conducted by restriction
endonuclease digestion of a polymerase chain reaction (PCR)
product as described by Bertina et al (1994; Figure 1).
Restriction endonuclease digestion of the CF V PCR product
with Mnl 1 resulted in three fragments of 22bp, 37bp and 116bp
(Figure 1).   In the presence of the A at 1691(CF V Leiden), one
of the recognition sites is blocked and the enzyme cuts only
once resulting in two fragments of 22bp and 153bp. Analysis
of the 20210 G to A substitution in the 3’-untranslated region
of the prothrombin gene was conducted by restriction
endonuclease digestion of the corresponding PCR product as
described by Poort et al (1996; Figure 2). The CF II PCR was
carried out using a mutagenised reverse primer 5’-ATA GCA
CTG GGA GCA TTG AAG C-3’ where the underlined adenosine
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base is absent from the wild type sequence.  The primer
together with the G20210A point mutation of CF II, created a
HindIII2 recognition site.  The undigested CF II PCR product
was 345bp long.  In the presence of the G20210A point
mutation, the CF II PCR product had one HindIII recognition
site resulting into two fragments, one of 322bp and one of 23bp
in length (Figure 2).
Statistical Analysis
The data were analysed statistically by the Hardy-Weinberg
Equilibrium, Fisher Exact test, Chi Square Contingency test
and Odds Ratio.
Results
All data are summarised in Table I
Coagulation Factor V
CF V restriction endonuclease digestion yielded 13 GA
heterozygotes (2.3%) and no abnormal homozygotes among
the newborn population and 9 GA heterozygotes (2.6%) and
no abnormal homozygotes among the senior citizen population.
No significant difference was observed between these two
populations. CF V restriction endonuclease digestion among
the referred patients yielded 23 GA heterozygotes (7.0%) and
no abnormal homozygotes.  The referred population
frequencies were found to be significantly different when
compared to the frequencies found in the random newborn
and the senior citizens (Table I).
Coagulation Factor II
CF II restriction endonuclease digestion yielded 7 GA
heterozygotes (2.7%) and no abnormal homozygotes among
the newborn population and 8 GA heterozygotes (2.4%) and
no abnormal homozygotes among the senior citizens.  No
significant difference was observed between these two
populations. CF II restriction endonuclease digestion among
the referred patients yielded 24 GA heterozygotes (7.3%) and
no abnormal homozygotes.  The referred population
frequencies were found to be significantly different when
compared to the frequencies found in the senior citizen
population (Table I). One trans-heterozygote was also found
among them.
Discussion
We have shown here that, somewhat contrary to
expectations, the allele frequency of the CF II G20210A and
the CF V G1691A, although high were practically the same
among the random newborn and the senior citizens in our
study.   Although both alleles increase the risk of thrombosis,
as shown by the finding of even higher frequencies (0.035 and
0.037) among the patients with a variety of clinical thrombosis
and the studies of others9-11, the relatively high frequency
should imply a positive element of natural selection, although
founder effects and genetic drift cannot be formally excluded.
The high frequency of haemolytic anaemia due to
haemogobinopathy and G6PD deficiency among populations
from geographic areas endemic for malaria12 or, possibly other
intra-erythrocytic parasites such as Leishmania, and, of Cystic
Fibrosis with respect to diarrhoeal virus13 are good examples
of positive natural selection.   One may assume that in the
Figure 2: Above: HindIII restriction map of CF II PCR
product Below: Separation of HindIII digested PCR
products on 6% PAGE. Lane 1 = PhiX/Hae III, lane 2 – 12 =
homozygote GG, lane 13 = undigested product, lane 10 =
heterozygote GA.
Figure 1: Above: Mnl1 restriction map of CF V PCR
product Below: Separation of MnlI digested PCR
products on 8% PAGE. Lane 1 = PhiX/Hae III, lane 2 – 8
= homozygote GG, lane 9 = heterozygote GA, lane 10 =
undigested product.
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A) Based on genetic analysis of random Maltese cord samples (24)  pooled together with recent cord analysis of 285 cord in
CF V Leiden and 126 cords in CF II.
B) Based on genetic analysis of patient samples that are referred to the Laboratory of Molecular Genetics for thrombosis
analysis
C) P- Value is greater than 0.05, the null hypothesis is accepted i.e. there is no significant difference between the frequencies
in Senior Citizens and the other group under study.
D) For significant difference at the 0.05 level, chi-square should be greater than or equal to 3.84. The null hypothesis is
accepted, i.e. the frequencies do not differ.
E) An OR > 1 indicates that there might be an association between the genotype and the phenotype or medical disorder.
Table 1: Genotype distribution and allele frequencies of CF V Leiden and CF II G20210A in Senior Citizens, Control Cords and
Referred Samples. The results of the statistical analysis are given for every mutation. Bold result means statistical significance.
26 Malta Medical Journal    Volume 17   Issue 01   March 2005
migration of humans out of Africa into Northern Europe either
the CF II G20210A or the CF V G1691A carrier could have
survived traumatic or obstetric bleeding better than their wild
type travellers.   Recently, it has been shown that the CF V
Leiden heterozygotes preferentially survived severe sepsis and
a similar observation was made on a mouse model of
endotoxaemia.14  Thus, natural selection appears a more
satisfactory and patho-physiologically sound explanation than
drift or founder effects. Based on our prior observation on the
population distribution of CF VII frameworks15, 16, we had
anticipated a lower frequency of one or both thrombogenic
alleles among the older subjects assuming that fatal thrombosis
would have decreased the number of surviving heterozygotes,
homozygotes and trans-heterozygotes.
The modern view of haemostasis places the CV VII-tissue
factor complex in a critical step for initiation and amplification
of thrombosis.  We15, 16 and others17-21 showed that the
production of CF VIIa is genetically regulated due to two
alternate forms of the CF VII gene with one being more active
than the other.  The allele frequency of the slower variant, CF
VII Framework II in Shinawi et al16  is found more frequently
among the older sector of the population.  Presumably, they
may have been protected from the “hypercoaguable” state by
the slow variant.  In this study, however, the results showed
no significant difference between the control newborn
population and the senior citizens population, implying that
the frequencies of both the CF V Leiden and the CF II G20210A
alleles did not change with age and thus did not reflect the
occurrence of fatal outcomes.
Similarly the frequency of the HFE allele of hereditary
haemochromatosis has been found higher among the elderly
in Sicily compared to younger subjects.22-24 Clearly, there must
be many other alleles of many other genes whose enrichment
among senior citizens compared to neonates, or vice versa,
provides an efficient tool for the discovery of “patho-
physiologically meaningful sequence variation” in man.
Thus, unlike CF VII frameworks, the CF II G20210A and
CF V G1691A alleles did not appear to increase the risk of fatal
thrombosis.   Alternatively the current level of healthcare in
Europe compensates for the additional risk.   The interplay
between alpha Thalassaemia and Hb S homozygotes (sickle
cell disease) provides grounds for comparison.25,26    A
concurrent alpha thalassaemia modifies the developmental
haematology of sickle cell disease with alpha plus thalassaemia
homozygotes having a much milder anaemia.   A higher
frequency of alpha Thalassaemia can be found among older
patients with sickle cell disease from less resourced countries
where health care is poor. We could not show any difference
among the patients from North America with appropriate
health care.26
There is a reciprocal North-South gradient in the relative
frequency of the CF II G20210A and  CFV G1691A alleles.  It
appears that because of the higher risk of the trans-
heterozygotes and homozygotes the higher frequency of one
allele could keep the other down.  Geographic gradients have
also been seen in beta-Thalassaemia with the b+ (Beta positive)
IVS-1, 6C thalassaemia being commoner in the Western
Mediterranean and the b+ (Beta positive) IVS-I , 110A
thalassaemia being commoner in the Eastern Mediterranean27.
In Cystic Fibrosis the CFTR; DF508 mutation frequency is
increased in the North and declines in the South except in Malta
and the Basque region of Spain.28 The geographic epidemiology
of alleles may well reflect the outcome of evolutionary pressures
on human migration, which resulted in contemporary
genomes.
These data strongly confirm the pathophysiologic risk of
thrombosis due to hypercoagulability among CF V G1619A, CF
II G20210A heterozygotes and trans-heterozygotes.   However,
the two mutations do not appear to influence mortality from
the clinical events.   In future studies it would be useful to
conduct prospective clinical follow up among CF V G1619A,
and CF II G20210A carriers conditioned on their CF VII
genotype and the response to therapeutic procedures.
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